Incisors Single-Unit Rehabilitation With Narrow GM Implants

November 8, 2023 updated by: Neodent

Incisors Single-Unit Rehabilitation With Narrow GM Implants: Observational Prospective Study

The Narrow GM Implants were designed for oral functional rehabilitation using dental implants, allowing for treatment of patients with different bone qualities in the region of lateral incisors in the maxilla or the region of lateral and central incisors in the mandible.

The objective of the study is to confirm the long-term safety and clinical performance of implants and abutments of the Narrow GM System in a daily dental practice setting, by means of a prospective collection of clinical data in an observational study using these devices.

Devices will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the instructions for use (IFU).

55 patients (needed to obtain a sample size of 55 implants) will be followed for 36 months and monitored for Adverse Events by the Investigators until the last protocol-related procedure of a patient is completed.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The study protocol was reviewed and approved by an Ethics Committee (CE) in Brazil.

The Narrow GM Implants were designed for oral functional rehabilitation using dental implants, allowing for treatment of patients with different bone qualities in the region of lateral incisors in the maxilla or the region of lateral and central incisors in the mandible.

The objective of the study is to confirm the long-term safety and clinical performance of implants and abutments of the Narrow GM System in a daily dental practice setting, by means of a prospective collection of clinical data in an observational study using these devices. Additionally, from the collected data, the study aims to identify previously unknown side-effects and monitor the known side-effects and contraindications stated on the Instruction for Use (IFU), identify and analyze emerging risks on the basis of factual evidence and ensure the continued acceptability of the benefit-risk ratio with the intent to verify that the intended purpose is correct for all JJGC products involved in the procedure that get in contact with the patient.

The sample will be prospectively selected and will consist of 55 patients, with at least one edentulous site in the region of lateral incisors in the maxilla and/or lateral and central incisors in the mandible, presenting natural adjacent and opposing tooth, and who are qualified for rehabilitation with narrow implants and single-unit fixed prostheses. Informed consent in writing will be obtained from each patient participating in the study prior to any study-related procedure.

GM Narrow implants will be placed under local anesthesia by guided or conventional surgery - as chosen by the surgeon - and with adequate bone bed preparation, as recommended by the manufacturer. Multiple implants can be placed in the same patient, as indicated. Implants must be installed 2mm infra-bony.

Data concerning the studied variables will be collected following the procedures and assessments plan by fulfilling the Case Report Form (CRF), in the following stages: First visit (Screening); TP - Implants placement; T0 - Implant Loading; TF - final prosthesis T6, T12, T24 and T36 - 6, 12, 24 and 36 months, respectively, after implant loading.

Panoramic radiographs, periapical radiographs, and computed tomography (CT) scans will be obtained from the region of interest before surgery, for surgical planning. Additionally, standardized digital periapical radiographs will be taken in a usual daily practice frequency, as determined by the investigator: after implants placement (TP - immediately or within 1 week after implant placement) and during the post-operative stages (T0, TF, T6, T12, T24, and T36) to assess the osseointegration process, changes in peri-implant bone level as well as prosthetic settlement and integrity.

Moreover, soft tissue evaluation will be conducted at the pre-treatment (Screening visit), for the regions to be rehabilitated with the study implants and in the postoperative period, at T0, TF, T6, T12, T24, and T36, for all study implants.

Study Type

Observational

Enrollment (Estimated)

55

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Goiás
      • Goiânia, Goiás, Brazil, 74070-070
        • Recruiting
        • Escola de Aperfeiçoamento Profissional dos Cirurgiões Dentistas de Goiás, EAPGOIAS.
        • Contact:
        • Principal Investigator:
          • Eduardo Zancopé, MSc
    • Minas Gerais
      • Uberlândia, Minas Gerais, Brazil, 38408-100
        • Recruiting
        • Universidade Federal de Uberlândia, Faculdade de Odontologia, Área de Oclusão Prótese Fixa e Materiais Odontológicos.
        • Contact:
        • Principal Investigator:
          • Flávio D Neves, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Patients presenting 18 years of age or more, with at least one edentulous site in the region of lateral incisors in the maxilla and/or lateral and central incisors in the mandible, who are qualified for rehabilitation with narrow implants and single-unit fixed prostheses.

Patients that give written informed consent to participate in this clinical study.

Description

Inclusion Criteria:

  • Patients with 18 years of age or more
  • At least one edentulous site in the region of lateral incisors in the maxilla and/or lateral and central incisors in the mandible
  • Presence of natural adjacent and opposing tooth,
  • Qualified for rehabilitation with narrow implants and single-unit fixed prostheses.

Exclusion Criteria:

As exclusion criteria, the contraindications, and warnings according to the Instructions for Use of the device will be applied, as follows:

  • Signs of allergy or hypersensitivity to titanium
  • Periodontal disease
  • heavy smoking/alcohol drinking habits
  • bruxism
  • high use of bisphosphonate drugs or proton pump inhibitors (PPIs)
  • radiation therapy
  • diabetes
  • autoimmune diseases
  • uncontrolled systemic complications or diseases
  • incomplete jawbone growth
  • bleeding disorders
  • HIV
  • osteoporosis
  • pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Narrow GM
Patients presenting at least onde edentulous site rehabilitated with Narrow GM implant
Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peri-implant bone level change
Time Frame: up to 36 months
Amount of peri-implant bone level change
up to 36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Periimplant bone level
Time Frame: up to 36 months
The peri-implant bone level will be measured on the periapical radiographs obtained as the distance between the coronal margin of the implant shoulder and the most coronal point of the peri-implant bone, on the mesial and distal surfaces of each implant. The horizontal measurement of the remodeling will be done, when there is no bone contact in the cervical part of the implant. This measurement will be performed from the superior site of the bone crest to the lateral edge of the implant, perpendicular to the long axis of the implant.
up to 36 months
Implant Survival
Time Frame: up to 36 months
Implant survival will be defined as the absence of implant loss at each follow-up.
up to 36 months
Implant success
Time Frame: up to 36 months

The implant success will be assessed according to:

  • Absence of persisting subjective discomfort such as pain, foreign body perception, and or dysaesthesia (painful sensation);
  • Absence of recurrent peri-implant infection with suppuration (infection is termed recurrent if observed at two or more follow-up visits after the treatment with systemic antibiotics);
  • Absence of implant mobility on manual palpation;
  • Absence of any continuous peri-implant radiolucency.
up to 36 months
Prosthetic Survival
Time Frame: up to 36 months
Prosthetic survival will be assessed as the final prosthesis remaining in situ at each follow-up, irrespective of its condition.
up to 36 months
Prosthetic Success
Time Frame: up to 36 months
Success will be defined as the prosthesis that remained unchanged and did not require any intervention, except routine occlusal adjustments, during the entire observational period.
up to 36 months
Patient Satisfaction with treatment: questionnaire
Time Frame: up to 36 months
Portuguese translation of the OHIP-14 [20,21] (Annex III) questionnaire will be used to assess Oral Health-Related Quality of Life (OHRQoL), as a measure of patient satisfaction with treatment. Patients will be asked how frequently they have been experiencing the problems assessed by the questionnaire.
up to 36 months
Clinician Satisfaction with treatment: questionnaire
Time Frame: up to 36 months
The assessment will be performed by means of a questionnaire using a visual analog scale (VAS) in the form of a 10 cm horizontal line, where 0 (left end) indicates minimum satisfaction and 10 (right end) indicates maximum satisfaction. The clinician will evaluate his/her satisfaction with the surgical procedure, experience with the use of the abutments, as well as with the surgical and prosthetic results obtained.
up to 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Waleska C Furquim, PhD, Neodent

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2022

Primary Completion (Estimated)

December 15, 2025

Study Completion (Estimated)

December 15, 2025

Study Registration Dates

First Submitted

February 9, 2022

First Submitted That Met QC Criteria

February 18, 2022

First Posted (Actual)

March 2, 2022

Study Record Updates

Last Update Posted (Estimated)

November 9, 2023

Last Update Submitted That Met QC Criteria

November 8, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Edentulous Alveolar Ridge

Clinical Trials on Narrow GM implants

3
Subscribe